CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-26 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −324 | $79.17 | $26K | 57,148 |
| 2026-05-26 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −3,800 | $79.39 | $302K | 53,348 |
| 2026-05-26 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −4,500 | $80.02 | $360K | 48,848 |
| 2026-05-26 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −551 | $80.71 | $44K | 48,297 |
| 2026-05-19 | Esposito Pamela Director | Option exercise | +1,000 | $31.20 | $31K | 1,000 |
| 2026-05-19 | Esposito Pamela Director | Option exercise · Stock Option (Right to Buy) | −1,000 | 9,000 | ||
| 2026-05-18 | Jacobs Bruce N. Chief Financial Officer | Option exercise | +15,000 | $2.08 | $31K | 247,588 |
| 2026-05-18 | Jacobs Bruce N. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −15,000 | 12,653 | ||
| 2026-05-11 | Ridloff Elena Director | Option exercise 10b5-1 | +3,000 | $31.20 | $94K | 3,000 |
| 2026-05-11 | Ridloff Elena Director | Sale 10b5-1 | −3,000 | $87.00 | $261K | 0 |
| 2026-05-11 | Ridloff Elena Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,000 | 13,000 | ||
| 2026-04-29 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 | +30,000 | $2.08 | $62K | 696,195 |
| 2026-04-29 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −17,005 | $80.74 | $1.4M | 679,190 |
| 2026-04-29 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −12,059 | $81.70 | $985K | 667,131 |
| 2026-04-29 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −936 | $82.45 | $77K | 666,195 |
| 2026-04-29 | Mainolfi Nello Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 215,559 | ||
| 2026-04-22 | Booth Bruce Director | Option exercise 10b5-1 | +5,641 | $14.18 | $80K | 5,641 |
| 2026-04-22 | Booth Bruce Director | Option exercise 10b5-1 | +259 | $20.00 | $5K | 5,900 |
| 2026-04-22 | Booth Bruce Director | Sale 10b5-1 | −5,900 | $89.96 | $531K | 0 |
| 2026-04-22 | Booth Bruce Director | Sale 10b5-1 | −88 | $90.08 | $8K | 3,899,829 |
Page 11 of 25 · 493 trades